Selected article for: "cardiovascular disease and chronic disease"
Author: Lee, Yong-ho; Kim, Jae Hyeon; Kim, So Ra; Jin, Heung Yong; Rhee, Eun-Jung; Cho, Young Min; Lee, Byung-Wan
Title: Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
  • Document date: 2016_11_8
    • ID: 4fwp1dnl_1
    Snippet: Obesity is a worldwide epidemic that leads to the development of chronic metabolic disorders, such as type 2 diabetes (T2D), cardiovascular disease, and non-alcoholic fatty liver disease (NALFD) (1) (2) (3) . NAFLD is a condition where fat, mainly triglycerides (TG), accumulates in the hepatocytes of patients who have not consumed excessive amounts of alcohol (4) . Estimates of the prevalence of NAFLD range from 6.3% to 33%, depending on the popu.....
    Document: Obesity is a worldwide epidemic that leads to the development of chronic metabolic disorders, such as type 2 diabetes (T2D), cardiovascular disease, and non-alcoholic fatty liver disease (NALFD) (1) (2) (3) . NAFLD is a condition where fat, mainly triglycerides (TG), accumulates in the hepatocytes of patients who have not consumed excessive amounts of alcohol (4) . Estimates of the prevalence of NAFLD range from 6.3% to 33%, depending on the population (5, 6) , and are expected to rise as obesity rates increase, populations become older, and physical activity levels decrease (4) . Moreover, there is an increased prevalence of NAFLD in T2D patients (7) , and its severity may be aggravated by T2D (8, 9) . However, beyond epidemiology, there are many challenges in the diagnosis and treatment of NAFLD.

    Search related documents:
    Co phrase search for related documents
    • cardiovascular disease and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cardiovascular disease and metabolic disorder: 1, 2, 3, 4, 5
    • cardiovascular disease and NAFLD prevalence: 1
    • cardiovascular disease and NALFD non alcoholic fatty liver disease: 1
    • cardiovascular disease and non alcoholic fatty liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • cardiovascular disease and physical activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cardiovascular disease and physical activity level: 1, 2, 3, 4, 5, 6
    • chronic metabolic disorder and metabolic disorder: 1, 2, 3
    • increase prevalence and liver disease: 1, 2, 3, 4
    • increase prevalence and NAFLD increase prevalence: 1, 2, 3
    • increase prevalence and NAFLD prevalence: 1, 2, 3
    • increase prevalence and NAFLD prevalence estimate: 1
    • increase prevalence and non alcoholic fatty liver disease: 1, 2
    • increase prevalence and obesity rate: 1, 2, 3, 4
    • increase prevalence and obesity rate increase: 1, 2, 3
    • increase prevalence and physical activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • liver disease and metabolic disorder: 1, 2, 3, 4, 5, 6, 7, 8
    • liver disease and non alcoholic fatty liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • liver disease and physical activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14